Clinical Trial

A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of Intravenous NAV-240 in Adults.

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to assess initial safety/tolerability of multiple doses of drug NAV-240. It will also learn about the profile and immunogenicity of drug NAV-240. The main question it aims to answer is: • What medical problems do participants have when taking multiple doses of drug NAV-240? Researchers will compare drug NAV-240 to a placebo (a look-alike substance that contains no drug) to see if any medical problems participants have differ between those taking drug NAV-240 and those taking placebo.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-10; most recent amendment 2026-03-04.
Status change: Recruiting → Completed 2025-12-18
Status change: Not Yet Recruiting → Recruiting 2025-06-04
Trial Details
NCT Number NCT06933043
Lead Sponsor Navigator Medicines, Inc.
Collaborators: Southern Star Research
Conditions Healthy Volunteers
Enrollment 24 participants
Start Date 2025-05-20
Primary Completion 2025-11-20 (estimated)
Study Completion 2025-11-20 (estimated)
Updated on ClinicalTrials.gov 2026-03-06